Angiomax bivalirudin: Additional Phase III data

Three-year follow-up data from the single-blind, international Phase III HORIZONS AMI trial in 3,602 patients showed that Angiomax given during angioplasty compared with heparin plus a GPIIb/IIIa inhibitor significantly reduced the incidence of cardiac-related death by 44% (2.9% vs. 5.1%, p=0.001); all-cause death by 25% (5.9% vs. 7.7%, p=0.03); reinfarction by 23% (6.2% vs. 8.2%, p=0.04); and rates of major bleeding by 36% (6.9% vs. 10.5%, p<0.001). There were no significant differences between treatment arms in the rates of major adverse cardiac events (17.3% vs. 17.8%, p=0.65) or stent thrombosis (4.5% vs. 5.1%, p=0.49). Data were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. ...